ArticleFrontiers in pharmacology2026
Interaction of nanoplastics with platelets: activation and fibrin clot formation.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Environmental exposure to micro- and nanoplastics (NPs) is an emerging toxicological concern, with recent evidence demonstrating their presence in human blood and vascular tissues. Although plastic-associated chemicals are known to induce oxidative stress and mitochondrial dysfunction, the direct impact of circulating NPs on blood cell function and redox-sensitive vascular processes remains poorly defined. Therefore, this study investigated the interaction between 100 nm carboxylated polystyrene nanoplastics (PS-NPs) and human platelets, which are key regulators of vascular homeostasis and thromboinflammation. Methods: The interaction and uptake of PS-NPs by human platelets were assessed using flow cytometry and fluorescence microscopy. To evaluate platelet activation, we measured cytoskeletal remodeling (via side scatter) and dense granule secretion (via CD63 externalization). Additionally, whole blood assays were conducted under calcium-permissive conditions to determine the impact of PS-NPs on the formation and structure of fibrin networks. Results: PS-NPs rapidly associated with human platelets in a time- and concentration-dependent manner, reaching near-maximal uptake within 10 minutes. Exposure to PS-NPs induced marked platelet activation, evidenced by significant cytoskeletal remodeling and concentration-dependent CD63 externalization at levels comparable to those induced by thrombin stimulation. Furthermore, in whole blood, PS-NPs promoted the formation of dense fibrin networks and were actively incorporated into the resulting fibrin matrix. Discussion: The rapid nature of PS-NP-platelet interactions suggests high-capacity physicochemical adsorption, potentially mediated by membrane lipid microdomains and protein corona formation. Notably, the observed procoagulant phenotype is consistent with the perturbation of redox-sensitive platelet activation pathways. Collectively, these findings identify platelets as direct cellular targets of nanoplastics and demonstrate that circulating particulate matter can acutely promote prothrombotic responses. These data support a model in which nanoplastic exposure contributes to cardiovascular risk through the dysregulation of redox-dependent vascular signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.